B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Hemophilia B

Trial Profile

B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Hemophilia B

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Eftrenonacog alfa (Primary) ; Nonacog alfa
  • Indications Haemophilia B
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms B-LONG
  • Sponsors Biogen Idec
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2017 According to a Swedish Orphan Biovitrum media release, data from this trial will be presented at the 10th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2017.
    • 18 Jul 2016 According to Biogen media release, joint data from subset of patients will be highlighted in oral and poster presentations at the World Federation of Hemophilia (WFH) 2016 World Congress in Orlando, Florida.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top